News: Merrimack Pharmaceuticals Inc (NASDAQ:MACK) belongs to Healthcare sector and Biotechnology industry. Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) recently reported that it will introduce at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 11, 2017, at 3:00 PM Pacific Time.
A live webcast of the presentation will be accessible in the Investors area of Merrimack’s site at investors.merrimack.com. A replay of the webcast will be documented there for two weeks taking after the presentation.
Summary: Merrimack Pharmaceuticals, Inc., a biopharmaceutical organization, takes part in finding, creating and commercializing prescriptions comprising of novel therapeutics matched with diagnostics for the treatment of malignancy basically in the United States. The organization offers ONIVYDE that is utilized for the treatment of patients with metastatic adenocarcinoma of the pancreas after malady movement taking after gemcitabine-based treatment. Its remedial oncology hopefuls in clinical improvement incorporate MM-398, which is in Phase II clinical trials for the treatment of patients with beforehand untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric strong tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic bosom disease. The companys helpful oncology hopefuls additionally incorporate MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, privately progressed or metastatic bosom growth; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, progressed non-little cell lung disease. Also, its remedial oncology hopefuls comprise of MM-141 that is in Phase II clinical trials for the treatment of beforehand untreated metastatic pancreatic disease patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with strong tumors. The organization has permit and cooperation concurrences with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; advancement, permit, and supply concurrence with Watson Laboratories, Inc.; sublicense and joint effort concurrence with PharmaEngine, Inc.; coordinated effort concurrences with Dyax Corp. furthermore, Adimab LLC,; and permit concurrence with University of California.